Key Takeaways Microbot gained a U.S. patent expanding LIBERTY's applications with modular tool-receiver units.The new patent increases Microbot's U.S. market opportunity from 2.5M to over 6M procedures.Shares have risen 7.1% after the news, with year-to-date gains of 195.5% against industry decline.Microbot Medical Inc. (MBOT) has been granted a new U.S. patent that broadens the potential applications of its LIBERTY Endovascular Robotic System. The patent covers a modular design that allows interchangeable ...

With the Newly Granted IP, the Company’s IP Portfolio for the LIBERTY® System now includes 12 patents granted globally and 57 patent applications pending. The Company Continues to Scale Commercial Readiness Plans for the LIBERTY® System as it Awaits FDA Decision. HINGHAM, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced that the United States Patent and Trademark Office (USPTO) has granted the Com ...

Core Insights - Microbot Medical Inc. is participating in the inaugural Endovascular Robotics session at the Society of Robotic Surgery (SRS) annual meeting, highlighting the growth and innovation in the endovascular robotics field driven by market demand [1][3] - The session will feature discussions on emerging technologies in the peripheral vascular, neurovascular, and cardiovascular spaces, with a focus on educating the medical community about the LIBERTY Endovascular Robotic System [2][3] - The SRS aims to foster education and collaboration in robotic surgery, providing opportunities for multi-centric studies and training for young professionals in the field [4] Company Overview - Microbot Medical is a pre-commercial stage medical technology company focused on redefining endovascular robotics and improving patient care globally [6] - The company has developed the world's first single-use, fully disposable endovascular robotic system, which aims to remove barriers to accessing advanced robotic systems [6] - The LIBERTY system is currently pending FDA 510(k) clearance and is not available for sale in the U.S. as the company strengthens its sales and marketing infrastructure for its launch [5]

Core Insights - Microbot Medical Inc. has been added to the Russell Microcap Index, effective June 30, 2025, enhancing its visibility in the market [1][2] - The inclusion reflects the company's strong execution and momentum, particularly in relation to its LIBERTY Endovascular Robotic System and ongoing FDA interactions [2] - The Russell US Indexes reconstitution captures the 4,000 largest US stocks, and membership in the Russell Microcap Index ensures automatic inclusion in relevant growth and value style indexes [2][3] Company Overview - Microbot Medical is a pre-commercial stage medical technology company focused on redefining endovascular robotics to improve patient care globally [4] - The company has developed the world's first single-use, fully disposable endovascular robotic system, aiming to overcome traditional barriers to advanced robotic systems [4] Market Context - Russell indexes are widely utilized by investment managers and institutional investors, serving as benchmarks for approximately $10.6 trillion in assets as of June 2024 [3]

Core Insights - Microbot Medical Inc. has been granted a critical patent in China for its LIBERTY Endovascular Robotic System, marking a significant step in its global intellectual property expansion strategy [1] - The company currently holds nine patents globally and has 59 pending patent applications, which helps maintain a competitive advantage and protect the unique capabilities of the LIBERTY System [2] - Preparations for the anticipated U.S. launch of the LIBERTY System are underway, with regulatory, operational, and commercial activities accelerating [3] - The company aims to impact both developed and emerging markets, with an estimated 2 million peripheral endovascular procedures performed annually in the U.S. and approximately 2.9 million in China [4] - Microbot Medical is focused on redefining endovascular robotics and improving patient care through its innovative, single-use, fully disposable robotic system [5]

Group 1 - Microbot Medical Inc. has been selected for inclusion in the preliminary list of additions to the Russell Microcap Index, effective after U.S. market close on June 27, 2025 [1] - Membership in the Russell Microcap Index is determined by market capitalization rankings and style attributes, and it remains in place for one year [2] - Russell indexes are utilized by investment managers and institutional investors for index funds and serve as benchmarks for approximately $10.6 trillion in assets as of June 2024 [3] Group 2 - Microbot Medical is a pre-commercial stage medical technology company focused on improving patient care globally [4] - The company has developed the LIBERTY Endovascular Robotic System, which is the world's first single-use, fully disposable endovascular robotic system [4]

Core Insights - Microbot Medical Inc. is reaffirming its expectation for the FDA's decision regarding the 510(k) clearance of its LIBERTY Endovascular Robotic System during the current second quarter [1][2] - The ACCESS-PVI trial data will be presented for the first time at a podium presentation on April 2, 2025, by Dr. Francois Cornelis from Memorial Sloan Kettering Cancer Center [1][2] Company Overview - Microbot Medical Inc. is a pre-commercial stage medical technology company focused on improving patient care globally [3] - The company has developed the world's first single-use, fully disposable endovascular robotic system, aiming to overcome traditional barriers to advanced robotic systems [3]